Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1/2 4Phase 2 1

Status

Recruiting 4Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Stomach Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Levoleucovorin × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06780111 2026-03-31

MK-3475-06E

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
298 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06428409 2026-01-22

MK-9999-02A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Fujian Cancer Hospital

Phase 1/2 Recruiting
51 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡